U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Fluoropyrimidine response

MedGen UID:
776457
•Concept ID:
CN184090
•
Sign or Symptom
Drug:
Fluoropyrimidine
MedGen UID:
452644
•Concept ID:
C0596581
•
Pharmacologic Substance
Any fluoropyrimidine-based agent with potential antineoplastic activity. As an antimetabolite, a fluoropyrimidine interferes with pyrimidine utilization and incorporation into DNA and RNA. [from NCI]
Fluoropyrimidine
 
Gene (location): DPYD (1p21.3)

Professional guidelines

PubMed

Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer.
Wang G, Huang Y, Zhou L, Yang H, Lin H, Zhou S, Tan Z, Qian J
Crit Rev Oncol Hematol 2024 Jun;198:104197. Epub 2023 Nov 10 doi: 10.1016/j.critrevonc.2023.104197. PMID: 37951282
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group
Eur Heart J 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244. PMID: 36017568
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M
Clin Pharmacol Ther 2018 Feb;103(2):210-216. Epub 2017 Nov 20 doi: 10.1002/cpt.911. PMID: 29152729Free PMC Article

Recent clinical studies

Etiology

MIR27A rs895819 TC genotype increases risk of fluoropyrimidine-induced severe toxicity independently of DPYD variations.
Ragia G, Biziota E, Koukaki T, Amarantidis K, Manolopoulos VG
Pharmacogenomics 2024 Jan;25(2):59-67. Epub 2024 Feb 14 doi: 10.2217/pgs-2023-0223. PMID: 38353109
MTHFR c.665C>T guided fluoropyrimidine therapy in cancer: gender-dependent effect on dose requirements.
Ioannou C, Ragia G, Balgkouranidou I, Xenidis N, Amarantidis K, Koukaki T, Biziota E, Kakolyris S, Manolopoulos VG
Drug Metab Pers Ther 2022 Sep 1;37(3):323-327. Epub 2022 Mar 11 doi: 10.1515/dmpt-2021-0219. PMID: 35272420
Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study.
Leichman CG, Benedetti JK, Zalupski MM, Hochster H, Shields AF, Lenz HJ, Wade Iii JL, Bearden Iii JD, Macdonald JS
Clin Colorectal Cancer 2005 Jul;5(2):119-23. doi: 10.3816/ccc.2005.n.024. PMID: 16098253

Diagnosis

MIR27A rs895819 TC genotype increases risk of fluoropyrimidine-induced severe toxicity independently of DPYD variations.
Ragia G, Biziota E, Koukaki T, Amarantidis K, Manolopoulos VG
Pharmacogenomics 2024 Jan;25(2):59-67. Epub 2024 Feb 14 doi: 10.2217/pgs-2023-0223. PMID: 38353109
Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study.
Leichman CG, Benedetti JK, Zalupski MM, Hochster H, Shields AF, Lenz HJ, Wade Iii JL, Bearden Iii JD, Macdonald JS
Clin Colorectal Cancer 2005 Jul;5(2):119-23. doi: 10.3816/ccc.2005.n.024. PMID: 16098253

Therapy

MIR27A rs895819 TC genotype increases risk of fluoropyrimidine-induced severe toxicity independently of DPYD variations.
Ragia G, Biziota E, Koukaki T, Amarantidis K, Manolopoulos VG
Pharmacogenomics 2024 Jan;25(2):59-67. Epub 2024 Feb 14 doi: 10.2217/pgs-2023-0223. PMID: 38353109
MTHFR c.665C>T guided fluoropyrimidine therapy in cancer: gender-dependent effect on dose requirements.
Ioannou C, Ragia G, Balgkouranidou I, Xenidis N, Amarantidis K, Koukaki T, Biziota E, Kakolyris S, Manolopoulos VG
Drug Metab Pers Ther 2022 Sep 1;37(3):323-327. Epub 2022 Mar 11 doi: 10.1515/dmpt-2021-0219. PMID: 35272420
Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study.
Leichman CG, Benedetti JK, Zalupski MM, Hochster H, Shields AF, Lenz HJ, Wade Iii JL, Bearden Iii JD, Macdonald JS
Clin Colorectal Cancer 2005 Jul;5(2):119-23. doi: 10.3816/ccc.2005.n.024. PMID: 16098253

Prognosis

MIR27A rs895819 TC genotype increases risk of fluoropyrimidine-induced severe toxicity independently of DPYD variations.
Ragia G, Biziota E, Koukaki T, Amarantidis K, Manolopoulos VG
Pharmacogenomics 2024 Jan;25(2):59-67. Epub 2024 Feb 14 doi: 10.2217/pgs-2023-0223. PMID: 38353109
miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation.
Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, Maiello E, Garcia-Foncillas J, Bandres E
Mol Cancer Ther 2010 Aug;9(8):2265-75. Epub 2010 Jul 20 doi: 10.1158/1535-7163.MCT-10-0061. PMID: 20647341
Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study.
Leichman CG, Benedetti JK, Zalupski MM, Hochster H, Shields AF, Lenz HJ, Wade Iii JL, Bearden Iii JD, Macdonald JS
Clin Colorectal Cancer 2005 Jul;5(2):119-23. doi: 10.3816/ccc.2005.n.024. PMID: 16098253

Clinical prediction guides

MIR27A rs895819 TC genotype increases risk of fluoropyrimidine-induced severe toxicity independently of DPYD variations.
Ragia G, Biziota E, Koukaki T, Amarantidis K, Manolopoulos VG
Pharmacogenomics 2024 Jan;25(2):59-67. Epub 2024 Feb 14 doi: 10.2217/pgs-2023-0223. PMID: 38353109
miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation.
Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, Maiello E, Garcia-Foncillas J, Bandres E
Mol Cancer Ther 2010 Aug;9(8):2265-75. Epub 2010 Jul 20 doi: 10.1158/1535-7163.MCT-10-0061. PMID: 20647341
Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study.
Leichman CG, Benedetti JK, Zalupski MM, Hochster H, Shields AF, Lenz HJ, Wade Iii JL, Bearden Iii JD, Macdonald JS
Clin Colorectal Cancer 2005 Jul;5(2):119-23. doi: 10.3816/ccc.2005.n.024. PMID: 16098253

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • Gene
      Related information in NCBI Gene
    • GTR
      Related information in GTR
    • GTR(Clinical)
      Clinical tests in GTR
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...